RECEIVED

Express Mail Label No. EV 246879918 US Attorney Docket No. 4409.214-US Serial No. 09/772,607

JAN 1 2 2004

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jonassen et al.

Attorney Docket No.: 4409.214-US

Application No.: 09/772,607

Group Art Unit: 1653

Filed: January 30, 2001

Examiner: Kam, C.

Confirmation No: 2082

For: Peptide Derivatives

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed. The references are as follows:

- 1. U.S. Patent No. 6,268,343
- 2. U.S. Patent No. 6,458,924

01/08/2004 CCHAU1 00000176 141447 09772607

01 FC:1806

180.00 DA

Express Mail Label No. EV 246879918 US Attorney Docket No. 4409.214-US Serial No. 09/772,607

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

This information disclosure statement is being filed after the period set forth in 37 C.F.R. 1.97(b), but **before** the mailing date of any of a final action, a notice of allowance, or an action that otherwise closes prosecution.

Accompanying this information disclosure statement is (check off either one)

the statement as specified in 37 C.F.R. § 1.97(e)

or

the fee set forth in 37 C.F.R. § 1.17(p) (currently \$180.00). Charge Deposit Account No. 14-1447 in the amount of \$180.00. A duplicate of this charge directive is attached.

Respectfully submitted,

Date: January 2, 2004

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Pharmaceuticals, Inc. 100 College Road West

Princeton, NJ 08540 (609) 987-5800

Use the following customer number for all correspondence regarding this application

23650
PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)

applicant.

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

Atty. Docket No. 4409.214-US

Serial No. DECEVE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT Applicant Jonassen et al. JAN 1 2 2004

AN 0 2 2004

(Use several sheets if necessary)

Filing Date
January 30, 2001

TO BE TECHT GENTER 1600/2000

			U.S. P	ATENT DOCUMENTS		TIO BENEENIER 1600				
RECEIVE	<u>-</u> n	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		G DATE		
NECEIVI		5,359,030	10/25/94	Ekwuribe	_			· ·		
JAN 1 2 2004										
			5				· ·			
CH CENTER 1600/2900		0		-						
·								· · · · ·		
								•		
			FOREIGN	PATENT DOCUMENTS	· · · · · · · · · · · · · · · · · · ·					
		DOCUMENT					TRANSLATION			
		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO		
· .		0 511 600	11/04/92	EPO						
		WO 93/15750	08/19/93	PCT						
		WO 93/21320	10/28/93	PCT						
·										
 :			~							
. —										
		OTHER DOCUMENTS	(Including Auth	or, Title, Date, Per	tinent Page	es, Etc.)				
·				g Accession No.	*					
· .		Abstract, F	File 434, Dial	og Accession No.	1261607	1				
			Abstract, File 434, Dialog Accession No. 12616071 Abstract, File 434, Dialog Accession No. 13565514 Chemical Abstracts, Vol. 123, No. 10, The Abstract No. 122862m							
		Chemical Abstracts, Vol. 118, No. 16, The Abstract No. 154346j								
		Chemical Ab	stracts, Vol.	118, No. 16. Th	ne Abstra	ct No. 154	346i			
· · · · · · · · · · · · · · · · · · ·		Chemical Ab	ostracts, Vol.	118, No. 16, Th	ne Abstra	ct No. 154	346j			
		Chemical Ab	ostracts, Vol.	118, No. 16, Th	ne Abstra	ct No. 154	346j			
	1		ostracts, Vol.		ne Abstra	ct No. 154	346j			
			ostracts, Vol.		ne Abstra	ct No. 154	346j			
					ne Abstra	ct No. 154	346j			
			ostracts, Vol.			ct No. 154	346j			
						ct No. 154	346j			

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to

O.E	FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTM PATENT AND	Atty. Docket No. 4409.214-US		Serial No. 09/772,607							
5/1/2	(C)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Jonassen et a	l.							
JAN 0 2	2004 💆	(Use several sheets if necessary)		Filing Date January 30,	2001	Group 1653						
<u> </u>	E ST		U.S. PATENT DOCUMENTS									
FRA PRA	DEM EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE					
_		6,268,343	7/31/01	Ellis	514	325						
Ē	7 06	6,458,924	10/1/02	Knudsen et al.	530	324						
	V 1 2 2004 TER 1600299											
RECEIVED	N I											
	CENT 14 N				<u> </u> .							
_	FOREIGN PATENT DOCUMENTS											
	~	DOCUMENT					TRANSLATION					
-		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO				
_												
_												
-												
_												
								<u></u>				
_		OTHER DO	OCUMENTS (Including	Author, Title, Date, Pertin	ent Pages, Etc	e.)						
-												
-												
	ļ											
•												
-												
•	EXAMINER	<u> </u>		DATE CONSIDERED								

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.